Stockscreener 앱 받기
3.685
1.21%
-0.045
시장 영업 전:
3.59
-0.095
-2.58%
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Bicycle Therapeutics plcADR Peer Comparison – Compare with Others - Value Research
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Renaissance Technologies LLC Buys 412,700 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz - The National Law Review
Bicycle Therapeutics (BCYC) Earnings Date and Reports 2026 - MarketBeat
Siren L.L.C. Trims Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks - TradingView
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? - Yahoo Finance
Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Enterprise value to EBIT forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC) - TradingView
Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
50BA Forecast — Price Target — Prediction for 2027 - TradingView
Bicycle Therapeutics shareholders approve all proposals at annual general meeting - Investing.com South Africa
BCYC - Finviz
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - Stock Titan
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - finance.yahoo.com
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - PR Newswire
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
BCYC: Q3 2025 featured higher R&D costs, a $59.1M net loss, and strong cash reserves supporting clinical progress - TradingView
Bicycle Therapeutics (BCYC) Stock Price, News & Analysis - MarketBeat
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
BCYC: Cost realignment and pipeline progress extend financial runway into 2028 amid higher R&D spend - TradingView
3.06%
2.55%
자본화:
|
볼륨(24시간):